CN108451949B - Application of paeoniflorin metabolite I in preparation of colitis treatment drug - Google Patents
Application of paeoniflorin metabolite I in preparation of colitis treatment drug Download PDFInfo
- Publication number
- CN108451949B CN108451949B CN201810633726.7A CN201810633726A CN108451949B CN 108451949 B CN108451949 B CN 108451949B CN 201810633726 A CN201810633726 A CN 201810633726A CN 108451949 B CN108451949 B CN 108451949B
- Authority
- CN
- China
- Prior art keywords
- paeoniflorin
- metabolite
- colitis
- mouse
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention researches the anti-inflammatory activity of paeoniflorin and paeoniflorin metabolite I through a DSS-induced colitis model. Experimental results show that paeoniflorin metabolite I has a good treatment effect on ulcerative colitis, compared with colon tissue damage degrees of a control group and a paeoniflorin group, a C57BL/6 mouse orally taking paeoniflorin metabolite I reduces colon tissue damage degrees of a mouse with a low-dose administration group and a mouse with a high-dose administration group taking paeoniflorin metabolite I, tissue structure layers are clear, infiltration of inflammatory cells of an lamina propria is reduced, the number of goblet cells is relatively increased, tissue edema and hyperemia are not seen in a mucous membrane muscular layer, and tissue morphology is obviously recovered. Proves that the paeoniflorin metabolite I has good treatment effect on the ulcerative colitis.
Description
Technical Field
The invention relates to the field of medicaments for treating colitis, in particular to application of paeoniflorin metabolite I in preparation of medicaments for treating colitis.
Background
Colitis (colitis) refers to inflammatory lesions of the colon caused by various causes. It can be caused by bacteria, fungi, viruses, parasites, protozoa, etc., or by allergy and physicochemical factors, and can be classified into specific inflammatory diseases and non-specific inflammatory diseases according to the cause of disease, wherein the former refers to infectious colitis, ischemic colitis, pseudomembranous colitis, etc., and the latter refers to ulcerative colitis and Crohn's disease of colon.
Ulcerative colitis is one of the more common diseases in digestive internal medicine, and the incidence of the ulcerative colitis is more and more along with the development of national economy and the improvement of life quality in recent years. The pathogenesis of ulcerative colitis is still unclear at present, and a plurality of experimental researches show that environmental factors, genetic factors, intestinal microorganisms and immune factors are closely related to the occurrence of ulcerative colitis. It is currently believed that the interaction of the body's immune system with intestinal microbes is probably one of the most important causes of the development and persistence of colonic inflammation. Because the pathogenesis of ulcerative colitis is not clarified yet, the current clinical treatment mainly uses anti-inflammatory drugs such as 5-aminosalicylic acid preparation and immunosuppressant such as glucocorticoid and azathioprine, and in recent years, novel drugs such as monoclonal antibody drugs play an important role in the treatment of ulcerative colitis, such as Infliximab, Adalimumab and Golimumab for blocking alpha tumor necrosis factor, but some patients with ulcerative colitis still have poor response to the treatment. In addition, patients who are effective in the above treatment also need long-term maintenance treatment, are easy to relapse, have great influence on the mind and body of the patients, and are also high in cost for social medical resources. Therefore, in recent years, many beneficial researches on new treatment methods for ulcerative colitis have been carried out, but the defects of difficult thorough cure, no targeted medicine and the like still exist. The traditional Chinese medicine for treating ulcerative colitis has a strong regulating effect on immune disorder of patients, has the characteristics of multiple links, multiple directions and multiple target points, has fewer side effects, has a higher clinical curative effect, and is easily accepted by patients. In the formula for treating ulcerative colitis in traditional Chinese medicine, white paeony root, red paeony root and the like are usually selected, and the traditional Chinese medicine has good effect by adopting the combined treatment modes of oral administration, enema and the like.
Paeoniflorin (Paeoniflorin) is an index component for measuring the content of Chinese medicinal materials of white paeony root (Paeoniacea radix alba) and red paeony root (Paeoniacea radix rubra) in the pharmacopoeia of the people's republic of China (2015 edition), and is also a main active component (the mass fraction is 384mg/g) in a white paeony root Total Glycoside (TGP) capsule which is a commercially available medicament for treating rheumatoid arthritis, and has good anti-inflammatory and immunoregulatory activities. However, studies have found that the oral absolute bioavailability of paeoniflorin is about 3% to 4%, presumably due to the conversion of paeoniflorin into metabolites in vivo. The paeoniflorin I is firstly obtained by a Japanese scholar through separation and purification in a culture solution after in-vitro transformation of a human intestinal flora, and then the scholars detect the paeoniflorin I in plasma and urine of a rat, and the royal jelly takes the paeoniflorin as a substrate and adopts an in-vitro lactic acid bacteria culture mode to separate and identify the paeoniflorin I from the transformation solution. However, the activity of paeoniflorin metabolite I has not been reported.
Disclosure of Invention
In order to solve the technical problems, the invention provides the following technical scheme:
the invention aims to provide application of paeoniflorin metabolite I in preparation of a colitis treatment drug.
The invention adopts a DSS-induced mouse colitis model to explore the anti-inflammatory activity of the paeoniflorin metabolite I, the paeoniflorin and the paeoniflorin metabolite I are respectively given after the mouse model is made, the normal saline is always given after the model is made, and the normal saline is continuously given for 10 days. By observing the weight of the rat, the length, the weight, the shape and the cell factor expression of the colon, the experimental result shows that the indexes of the paeoniflorin metabolite I group are obviously superior to those of the modeling group and the paeoniflorin group, and the effect of 5mg/kg of the paeoniflorin metabolite I is the best.
Preferably, the colitis mentioned in the above application is ulcerative colitis.
Preferably, in the application, the dosage of the paeoniflorin metabolite I is 5 mg/kg.
The other purpose of the invention is to provide a pharmaceutical composition for treating colitis, wherein the pharmaceutical composition is paeoniflorin metabolite I, or paeoniflorin and paeoniflorin metabolite I.
Preferably, the dosage of the paeoniflorin metabolite I in the pharmaceutical composition is 5 mg/kg.
The invention also aims to provide a medicinal preparation for treating colitis, which is prepared from the medicinal composition and conventional medicinal auxiliary materials.
Preferably, the pharmaceutical preparation is an oral pharmaceutical preparation or rectal suppository or enema granules. Further preferably, the medicament is an oral medicament preparation.
In the animal modeling experiment, the C57BL/6 mouse is used as an animal model, and the result of the intragastric administration proves that the paeoniflorin metabolite I has a practical treatment effect on DSS-induced colitis.
The invention also aims to provide a health-care product for colitis, which is prepared from the medicinal composition and conventional auxiliary materials.
The fifth purpose of the invention is to provide the application of paeoniflorin metabolite I in preparing the medicine for protecting colon mucosal epithelium.
The invention aims at providing the application of paeoniflorin metabolite I in preparing the medicine for eliminating colonic mucosa edema.
Animal modeling experiment results show that paeoniflorin metabolite I can remarkably repair damaged colon tissues, has clear tissue hierarchical structure, reduces infiltration of inflammatory cells in an indigenous layer, increases the number of goblet cells, does not show tissue edema and congestion in a mucous membrane muscular layer, and remarkably recovers the tissue morphology. Therefore, the paeoniflorin metabolite I can be applied to the preparation of medicaments for protecting colonic mucosa epithelium and medicaments for eliminating colonic mucosa edema.
The invention has the advantages of
1. The invention proves the treatment effect of the paeoniflorin metabolite I on colitis through experiments, provides the administration dosage for treating the paeoniflorin metabolite I and provides a new research direction for treating colitis.
2. The invention proves that paeoniflorin metabolite I can practically play a role in treating colitis, and compared with the method for treating colitis by adopting a formula, the method for treating colitis by adopting paeoniflorin metabolite I is more convenient to use and more economic in cost and has obvious progress compared with the prior art.
Drawings
The accompanying drawings, which are incorporated in and constitute a part of this application, illustrate embodiments of the application and, together with the description, serve to explain the application and are not intended to limit the application.
FIG. 1 is a graph showing the change in body weight of a mouse molded in example 1 during administration;
FIG. 2 is a graph showing the changes in colon length and weight of mice modeled in different experimental groups in example 1;
FIG. 3 is a colon histogram and HE staining chart of the mouse model of example 1;
FIG. 4 is a graph showing the expression of cytokines in serum in example 1.
Detailed Description
It should be noted that the following detailed description is exemplary and is intended to provide further explanation of the disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.
It is noted that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of example embodiments according to the present application. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, and it should be understood that when the terms "comprises" and/or "comprising" are used in this specification, they specify the presence of stated features, steps, operations, devices, components, and/or combinations thereof, unless the context clearly indicates otherwise.
As introduced in the background art, the prior art has no technical problems of good drug pertinence, difficult thorough healing and the like for ulcerative colitis, and in order to solve the technical problems, the application provides the application of paeoniflorin metabolite I in preparing the drug for treating colitis.
In a typical embodiment of the present application, there is provided a use of paeoniflorin metabolite I for preparing a medicament for treating colitis.
In a preferred embodiment, the colitis is ulcerative colitis.
In a preferred embodiment, the above-mentioned paeoniflorin metabolite I is administered in a dose of 5 mg/kg.
In another exemplary embodiment of the present application, a pharmaceutical composition for colitis is provided, which is paeoniflorin metabolite I, or paeoniflorin and paeoniflorin metabolite I.
In a preferred embodiment, the dosage of paeoniflorin metabolite I in the above pharmaceutical composition is 5 mg/kg.
In another exemplary embodiment of the present application, a pharmaceutical preparation for colitis is provided, which is prepared from the pharmaceutical composition and conventional pharmaceutical excipients.
In a preferred embodiment, the pharmaceutical preparation is an oral preparation, or rectal suppository or enema granules, wherein the oral preparation has a better effect.
In another exemplary embodiment of the present application, a health product for colitis is provided, which is prepared from the pharmaceutical composition and conventional adjuvants.
In another exemplary embodiment of the present application, there is provided a use of paeoniflorin metabolite I for preparing a medicament for protecting colonic mucosal epithelium.
In another exemplary embodiment of the present application, there is provided a use of paeoniflorin metabolite I for preparing a medicament for eliminating colonic mucosal edema.
In order to make the technical solutions of the present application more clearly understood by those skilled in the art, the technical solutions of the present application will be described in detail below with reference to specific examples and comparative examples.
Experimental animals in this example: c57BL/6 mice, female, 8 weeks old, weight 18-24g, provided by Beijing Wittingle laboratory animal technology Co., Ltd (animal quality certificate number: SCXK (Jing 2012-001)), and the temperature of the rearing room is 23 +/-1 ℃.
Experimental reagent: dextran sulfate sodium salt (DSS), molecular weight: 36000 and 40000, purchased from MP company of America. The ELISA kit was purchased from Guangzhou Chenran Biotech Ltd. TDZ5-WS multi-rack automatic balance centrifuge from Changshan instrument centrifuge instruments Ltd; the DKZ series electric heating constant temperature oscillation water tank is purchased from Shanghai constant technology Limited; iMark Microplate Reader is available from BIO-RAD.
Example 1
MTT assay
Taking thymus gland tissue of C57BL/6 adult mouse, grinding and extracting to obtain mature lymphocytes of the mouse, culturing, inoculating normal lymphocytes in logarithmic phase into a 96-well plate for MTT test, and inoculating 1 × 10 lymphocytes in each well5A cell. Paeoniflorin as control group with concentration of 0.25mg/ml,0.5mg/ml g,1mg/ml,2mg/ml,4 mg/ml; the experimental group was paeoniflorin metabolite I, added at concentrations of 1.25. mu.g/ml, 2.5. mu.g/ml, 5. mu.g/ml, 10. mu.g/ml and 20. mu.g/ml, with three wells in parallel per group. After 72 hours of treatment, MTT was added and the result of measurement by a microplate reader showed that the IC50 value of paeoniflorin to normal cells was 1mg/ml and the IC50 value of paeoniflorin metabolite I to normal lymphocytes was 5. mu.g/ml.
2. Animal modeling experiment
2.1 establishment of C57BL/6 mouse colitis model
DSS was dissolved in distilled water to prepare a 3.5% DSS (W/W) solution, which was freely drunk by C57BL/6 mice for 7 days instead of drinking water, and was changed every day. The feed was freely ingested as a standard laboratory animal mouse feed (supplied by Beijing Wittingle laboratory animal technology Co., Ltd.).
2.2 animal administration
The C57BL/6 mice are divided into 5 groups, namely a normal mouse control group, a model mouse control group and 2 different paeoniflorin metabolite-I concentration treatment groups, wherein each group of the paeoniflorin treatment groups comprises 8 mice and each half of the mice are male and female. Model group and paeoniflorin metabolite I-treated group 3.5% DSS was freely drunk continuously for seven days, and then changed to tap water until day 11. Paeoniflorin was prepared to a final concentration of 5mg/ml (50mg/kg) with normal saline, paeoniflorin metabolite I was prepared to a homogeneous solution of 0.2mg/ml (2mg/kg) and 0.5mg/ml (cell IC50 value, 5mg/kg) with normal saline, and the solution was mixed by ultrasonic oscillation before use, and the three distilled water group was used as a model control group, and the normal control group was used for drinking water normally. The gavage dose of each mouse was 0.2ml per day from the first day, and the gavage was continued for 10 days.
2.3 animal model indices
2.3.1 mouse weight changes
The mice were weighed daily and the weight changes of the mice were recorded.
2.3.2 Length and weight of Colon in mice
The mice were sacrificed by cervical dislocation, the abdomen was dissected, the colon from the anus to the ileocecal region was taken and the length of the colon was measured, and the weight of the entire colon was weighed. The colon length was recorded in detail at the time of dissection of each mouse, and there is data indicating that the DSS colitis model is characterized by edema, shortening of the colon, which can be used to some extent as an indicator of the severity of inflammation.
2.3.3 HE staining for Colon morphological changes
Cutting the middle segment of colon about 0.5cm, cleaning with normal saline, rapidly fixing in 4% formaldehyde, embedding in paraffin, HE staining, and observing under light microscope.
2.3.4 measurement of cytokine expression
A colon of about 1cm in length was taken, washed with ice physiological saline at 4 ℃ to remove blood stains, blotted with filter paper, and weighed. 50mmo1/L phosphate buffer (PBS, pH 6.0, 0.1g/m L) was added depending on the colon weight. Homogenizing in ice bath with ultrasonic homogenizer, centrifuging at 10000Xg for 20min, collecting supernatant, and keeping at-20 deg.C. ELISA for IL-6 detection: adding 100 mu L of IL-6 standard substance/sample into each well, sealing, incubating at 37 ℃ for 1h, adding 100 mu L of biotinylated antibody, sealing, incubating at 37 ℃ for 1h, washing the plate for 5 times, adding 100 mu L of streptavidin-treated HRP solution, sealing, incubating at 37 ℃ for 0.5h, washing the plate for 5 times, adding 100 mu L of LTMB substrate solution, incubating at 37 ℃ for 20min, adding 100 mu L of stop solution, stopping the reaction, and measuring the wavelength at 450 nm.
3. Results of the experiment
3.1 mouse weight changes
As shown in figure 1, after DSS modeling, weight loss occurred from day 3 to the end of the modeling, and the weight of the mice in each group was significantly reduced compared to the control group. The average body weight of mice with paeoniflorin metabolite I was significantly increased compared to the model group, wherein the 5mg/kg dose of paeoniflorin metabolite I had the best effect.
3.2 Colon and weight changes in mice
As shown in figure 2, the length and weight of colon of each group of mice are significantly lower than those of control group, and the length and weight of colon are significantly increased after administration of paeoniflorin or paeoniflorin-I, wherein the effect of paeoniflorin-I at 5mg/kg dose is the best.
3.3 HE staining results
As shown in figure 3, the colon tissue of the model group mouse is seriously damaged, the basic structure of the mucosa is damaged, a large amount of goblet cells are lost, the infiltration of lymphocyte in the lamina propria is obvious, and the tissue edema and congestion can be seen in the muscularis mucosa; the damage degree of colon tissues of mice in a paeoniflorin administration group is reduced, but the tissue structure chromatography is not clear; the damage degree of colon tissues of mice in a low and high dose administration group of paeoniflorin metabolite I is reduced, the tissue structure level is clear, the infiltration of inflammatory cells in an indigenous layer is reduced, the number of goblet cells is relatively increased, the mucosal muscular layer has no tissue edema and congestion, and the tissue morphology is obviously recovered.
3.4 ELISA detection of cytokine expression in the sera of the groups
As shown in FIG. 4, the administered group showed a decrease in the contents of IL-6, IL-1, IL-10 and TNF-. alpha.in colon tissue as compared with the model group.
4. Conclusion
The anti-inflammatory activity of paeoniflorin and paeoniflorin metabolite I was studied using a DSS-induced colitis model. 40C 57BL/6 mice were randomly divided into 5 groups (normal mouse control group, model mouse control group, 2 different paeoniflorin metabolite-I concentration treatment groups, paeoniflorin treatment group) with 8 mice each. After modeling, mice are respectively administered with 50mg/kg of paeoniflorin, 2mg/kg of paeoniflorin metabolite I and 5mg/kg of paeoniflorin metabolite I through intragastric administration, after model modeling, the mice are administered with normal saline, and normal groups are always administered with the normal saline. The administration was continued for 10 days, and after the administration, the body weight of the rat, the length and weight of the colon, the colon morphology and the cytokine expression were observed. The results show that the body weight of each group of mice subjected to model making is obviously reduced, and the paeoniflorin metabolite-I group with the dose of 5mg/kg is obviously increased compared with the model group; the length and weight of colon after administration of paeoniflorin or paeoniflorin metabolite-I are obviously increased compared with those of the model group, wherein the paeoniflorin metabolite-I with the dose of 5mg/kg has the best effect; compared with the colon tissue injury of a mouse in a model group, the low and high dose administration group of paeoniflorin metabolite I can obviously repair the injured colon tissue, and the HE staining result shows that the shape of the colon tissue is obviously recovered; ELISA detection results of cytokine expression in serum of each group show that the contents of IL-6, IL-1, IL-10 and TNF-alpha in colon tissues are obviously reduced in the administration group compared with the model group.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (1)
1. The application of the paeoniflorin metabolite I in preparing a medicine for treating colitis is characterized in that the administration dose of the paeoniflorin metabolite I is 5 mg/kg; the colitis is ulcerative colitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810633726.7A CN108451949B (en) | 2018-06-20 | 2018-06-20 | Application of paeoniflorin metabolite I in preparation of colitis treatment drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810633726.7A CN108451949B (en) | 2018-06-20 | 2018-06-20 | Application of paeoniflorin metabolite I in preparation of colitis treatment drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108451949A CN108451949A (en) | 2018-08-28 |
| CN108451949B true CN108451949B (en) | 2021-03-19 |
Family
ID=63216246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810633726.7A Active CN108451949B (en) | 2018-06-20 | 2018-06-20 | Application of paeoniflorin metabolite I in preparation of colitis treatment drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108451949B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110343657B (en) * | 2019-01-23 | 2021-02-19 | 华南农业大学 | Method for establishing mouse primary colon mucosal epithelial cell inflammation model induced by combination of dextran sodium sulfate and lipopolysaccharide |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100292A (en) * | 2009-12-17 | 2011-06-22 | 苏州知微堂生物科技有限公司 | Functional confectionary with scutellaria baicalensis sugar and preparation technology thereof |
| CN107397752A (en) * | 2016-10-11 | 2017-11-28 | 张作光 | Purposes of the albiflorin in the product for improving gut flora systemic-function is prepared |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100584954C (en) * | 2006-05-15 | 2010-01-27 | 中国科学院成都生物研究所 | Method for producing paeonin metabolite-I by short lactobacillin fermentation |
| CN104189006B (en) * | 2014-08-28 | 2018-06-01 | 中国中医科学院中医基础理论研究所 | A kind of composition with anti-inflammatory effect |
-
2018
- 2018-06-20 CN CN201810633726.7A patent/CN108451949B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102100292A (en) * | 2009-12-17 | 2011-06-22 | 苏州知微堂生物科技有限公司 | Functional confectionary with scutellaria baicalensis sugar and preparation technology thereof |
| CN107397752A (en) * | 2016-10-11 | 2017-11-28 | 张作光 | Purposes of the albiflorin in the product for improving gut flora systemic-function is prepared |
Non-Patent Citations (1)
| Title |
|---|
| 芍药苷的微生物转化研究;王晓玲;《西南民族大学学报自然科学版》;20110517;第37卷(第3期);第425-430页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108451949A (en) | 2018-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | Baicalin is curative against rotavirus damp heat diarrhea by tuning colonic mucosal barrier and lung immune function | |
| WO2021052305A1 (en) | Use of eight-treasure pill in preparation of medicine for preventing or treating diseases related to il-6 inflammatory cytokine storm | |
| WO2011153929A1 (en) | New use of icariin and epimedium flavonoids containing icariin | |
| CN108451949B (en) | Application of paeoniflorin metabolite I in preparation of colitis treatment drug | |
| CN114028453A (en) | Broad-spectrum antiviral drug, and pharmaceutical composition and application thereof | |
| WO2024016996A1 (en) | Use of naphthoquine phosphate in preparation of medicament for treating autoimmune diseases | |
| Liu et al. | Artemisinin derivative TPN10466 suppresses immune cell migration and Th1/Th17 differentiation to ameliorate disease severity in experimental autoimmune encephalomyelitis | |
| Sun et al. | Gingko biloba extract (Ginaton) ameliorates dextran sulfate sodium (DSS)-induced acute experimental colitis in mice via reducing IL-6/STAT3 and IL-23/IL-17 | |
| WO2021017339A1 (en) | Application of hydroxysafflor yellow a in preparation of medication for treatment or adjuvant treatment of obesity disease | |
| TWI435727B (en) | Use of modulating secretion of cytokines | |
| CN112691114B (en) | Application of momordica polysaccharide in preparation of medicine for treating ulcerative colitis and pharmaceutical preparation of momordica polysaccharide | |
| CN109589329B (en) | Pharmaceutical composition for reducing brain injury caused by stroke by applying rosmarinic acid | |
| CN111358782A (en) | Application of imipenem in preparation of medicine for treating inflammatory storm caused by infectious diseases | |
| CN112546202A (en) | Complexing agent with HPV virus inhibiting function and preparation method thereof | |
| CN114712379B (en) | Application of astragaloside IV in preparing medicine for preventing and treating peritoneal dialysis intestinal complications | |
| CN117137897B (en) | Application of sofalcone in preparation of medicine for preventing/treating psoriasis | |
| CN114344319B (en) | Application of evodiaoside in preparation of anti-inflammatory drugs and/or immunosuppressant drugs | |
| CN116850180B (en) | Application of cork xanthoxylin in preparing medicament for treating rheumatoid arthritis | |
| CN114209812B (en) | Application of alpha-Momordica charantia extract in preparation of anti-inflammatory drugs | |
| CN115400119A (en) | Medical application of arteether maleate in treating non-alcoholic fatty liver disease | |
| Huang et al. | Dictamnine ameliorates DNFB-induced atopic dermatitis like skin lesions in mice by inhibiting M1 macrophage polarization and promoting autophagy | |
| Maki et al. | Larvicidal effect of flubendazole on Angiostrongylus cantonensis in mice with various worm burdens | |
| CN112426422A (en) | Application of pyridine carboxamide derivative AMSP-30m in preparation of drugs for preventing and treating rheumatoid arthritis | |
| CN118027006A (en) | 2, 4-Diaminopyrimidine derivative and preparation method and application thereof | |
| CN117462550A (en) | Ledebouriella root lactone derivative and application of pharmaceutical composition thereof in preventing and treating kidney fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |